Global Oral Anorexiant Drug Market Growth 2024-2030

Global Oral Anorexiant Drug Market Growth 2024-2030

Oral anorexiant drugs are medications designed to suppress appetite and reduce food intake, aiding in weight loss for individuals who are overweight or obese. These drugs typically act on the central nervous system, either by stimulating the release of certain neurotransmitters like norepinephrine and dopamine, which can create a feeling of fullness, or by blocking the reuptake of these chemicals, prolonging their appetite-suppressing effects. Commonly prescribed oral anorexiants include phentermine, diethylpropion, and lorcaserin. They are often used in conjunction with lifestyle modifications such as diet and exercise to enhance weight loss results. However, these medications can have side effects such as increased heart rate, elevated blood pressure, insomnia, and potential for abuse or dependency, and they are usually recommended for short-term use under medical supervision.

The global Oral Anorexiant Drug market size is projected to grow from US$ 767 million in 2024 to US$ 1102 million in 2030; it is expected to grow at a CAGR of 6.2% from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “Oral Anorexiant Drug Industry Forecast” looks at past sales and reviews total world Oral Anorexiant Drug sales in 2023, providing a comprehensive analysis by region and market sector of projected Oral Anorexiant Drug sales for 2024 through 2030. With Oral Anorexiant Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oral Anorexiant Drug industry.

This Insight Report provides a comprehensive analysis of the global Oral Anorexiant Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Oral Anorexiant Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oral Anorexiant Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oral Anorexiant Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oral Anorexiant Drug.

United States market for Oral Anorexiant Drug is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Oral Anorexiant Drug is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Oral Anorexiant Drug is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Oral Anorexiant Drug players cover Akrimax Pharmaceuticals, Janssen Ortho, Roche Pharmaceuticals, Teva Pharmaceuticals, Arena Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly

% in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Oral Anorexiant Drug market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Catecholamines
Serotonin

Segmentation by Application:
Hospitals
Clinics
Retail Sales
Online Pharmacies
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Akrimax Pharmaceuticals
Janssen Ortho
Roche Pharmaceuticals
Teva Pharmaceuticals
Arena Pharmaceuticals
Abbott Pharmaceuticals
Epic Pharma
Novo Nordisk
Patheon Pharmaceuticals
Recordati Rare Diseases
Catalent Pharma Solutions
MOVA Pharmaceuticals

Key Questions Addressed in this Report

What is the 10-year outlook for the global Oral Anorexiant Drug market?

What factors are driving Oral Anorexiant Drug market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Oral Anorexiant Drug market opportunities vary by end market size?

How does Oral Anorexiant Drug break out by Type, by Application?



Please note: The report will take approximately 2 business days to prepare and deliver.